SCPH: scPharmaceuticals Company Value to Net Income

Corporate emblem and logo of scPharmaceuticals (SCPH)

Cash flows for scPharmaceuticals Inc. (SCPH) remain volatile due to the initial rollout phase of its infusion products. This market valuation chart reflects a current figure of -3.30. Business growth relies on the implementation of Furoscix for home-based heart failure therapy, which provides benefits to insurers. Meanwhile, existing capital is sufficient to cover all launch costs for the cardiology drug, despite a planned reduction in reserves.

SCPH scPharmaceuticals, Inc.: Price to Earnings Ratio in the range 07/04/2022 - 10/18/2025

Comprehensive metric breakdowns and analytics for scPharmaceuticals, Inc. (SCPH)

- price and consensus price forecast:
Stock Price scPharma|SCPH - Consensus Target
- market capitalization information:
Market Value scPharmaceuticals Inc.|SCPH - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share scPharmaceuticals|SCPH - Company Net Assets|Market Cap to Book Value Multiple scpharmaceuticals.com|SCPH - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio scPharmaceuticals Inc.|SCPH - Long-Term Debt to Capital|Current Liabilities to Capital scPharma|SCPH - Company Debts|Debt to Net Assets Ratio scPharmaceuticals Inc.|SCPH - Company Long-Term Debt|Short-Term Debt Volume scPharmaceuticals|Quick Liquidity Indicator scpharmaceuticals.com
- business earnings and investment ratios data:
SCPH - Company Net Income|Forward Earnings scPharmaceuticals Inc.|SCPH - P/E Multiple|Future Price to Earnings Multiple scPharma|SCPH - PEG Multiple|EV/EBITDA Multiple scPharmaceuticals Inc.|SCPH - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year scPharmaceuticals|SCPH - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months scpharmaceuticals.com|SCPH - Earnings growth in current year|Earnings growth forecast for next year scPharmaceuticals Inc.
Comprehensive company analysis:scpharmaceuticals.com - SCPH
Flagship merchandise of scPharmaceuticals

The P/E ratio determines the market value of a business relative to its net income, serving as a measure of investment attractiveness. This metric is sensitive to currency fluctuations and revenue dynamics, which is directly reflected in the current valuation P/E of the company. Low values may signal an undervaluation or a systemic crisis in profitability. For scPharmaceuticals Inc. (SCPH), this indicator confirms the effectiveness of the strategy to transition patients to home treatment using the Furoscix system.

Analysis of competing companies

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|Business Payback Period ARS Pharmaceuticals Inc (SPRY)|Theravance - P/E Multiple|Aquestive Corp (AQST) - Price to Earnings Ratio|tectonictx.com (TECX) - Price to Earnings Ratio|Market Cap to Net Income TNXP (tonixpharma.com)|SXTC (SXT Pharmaceuticals) - P/E Multiple|EPRX: Company Value to Net Income|P/E Multiple BHST|P/E Multiple Invizyne (EXOZ)|Price to Earnings Ratio Oramed Pharmaceuticals Inc. ORMP|Company Value to Net Income ENTX|HYFT - Price to Earnings Ratio|ABVC BioPharma Inc. (ABVC) - Price to Earnings Ratio|CPIX: P/E Multiple|Quantum BioPharma Corp (QNTM) - P/E Multiple|FGEN (FibroGen, Inc.) - P/E Multiple|Price to Earnings Ratio telomirpharma.com (TELO)|P/E Multiple RANI|SNYR - Market Cap to Earnings|Rallybio - Price to Earnings Ratio|P/E Multiple Lexaria Bioscience Corp LEXX|PULM: Price to Earnings Ratio|Pheton Holdings Ltd - Market Price to Net Income Ratio|APM: P/E Multiple|LYRA - Business Payback Period|IBO (Impact BioMedical) - P/E Multiple|Price to Earnings Ratio TNF Pharma (TNFA)|P/E Multiple YCBD|P/E Multiple painreform.com (PRFX)|Price to Earnings Ratio Altamira Therapeutics Ltd. CYTO|Lipella Pharmaceuticals Inc - Price to Earnings Ratio|OPTN - Price to Earnings Ratio|Business Payback Period Pieris Pharma PIRS|PROC (Procaps Group S.A.) - Price to Earnings Ratio|petrospharma.com - Company Value to Net Income|QLI (Qilian International Holding) - P/E Multiple|Acelyrin Inc. (SLRN) - Business Payback Period|Price to Earnings Ratio TFF Pharma (TFFP)